The role of immune checkpoint inhibitors in NSCLC

Bookmark and Share
Published: 27 Jan 2021
Views: 2240
Dr Maurice Pérol, Centre Léon Bérard, Lyon, France

Dr Maurice Pérol presents an overview of evidence-based best practice recommendations on the use of PD-1 inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Dr Pérol summarises the indications for atezolizumab, durvalumab and pembrolizumab in NSCLC, as well as the factors that should be considered when selecting between these agents, including performance status, need for rapid treatment, bulkiness of disease, toxicity and presence of liver/brain metastases.

This presentation is a supporting resource for the Classroom to Clinic module “Biomarkers & predicting response to PD-1/PD-L1 inhibitors”. Classroom to Clinic is a complete group learning package that allows you to build tailored CME-accredited meetings in minutes, and confidently deliver an effective meeting specific to the needs of your learners. To explore Classroom to Clinic resources and more accredited CME, please visit Oncology Knowledge into Practice.

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME and validated by an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.